Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients

Annales de Biologie Clinique

Volumn 69, Issue 6, 2011, Pages 671-677

  Amine, Khadija ^a   Atouk, Abdelouahed ^a   Moussamih, Samya ^b   Saile, Rachid ^a   Mikou, Afaf ^c   Kettani, Anass ^a  

^a HASSAN II UNIVERSITY   (Morocco)

^b biotechnologie et environnement   (Morocco)

^c FACULTÉ DES SCIENCES AIN CHOCK   (Morocco)

Author keywords

Cardiovascular diseases; Coronary artery diseases; Paraoxanase 1; Type II diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PON1 PROTEIN, HUMAN; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; FEMALE; HUMAN; HYDROLYSIS; LIPID METABOLISM; MALE; METABOLISM; METABOLOME; MIDDLE AGED; PHYSIOLOGY;

AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYDROLYSIS; LIPID METABOLISM; MALE; METABOLOME; MIDDLE AGED; PARAOXON; TRIGLYCERIDES;

EID: 82255161889     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0648     Document Type: Article

References (37)

1. Caroline E, Katie O, Lena B, Jane W, Andrew S. Family history of cardiovascular disease is associated with cardiovascular responses to stress in healthy young men and women. Int J Psychophysiol 2007 ; 63 : 275-82.
2. Ruderman NB, Gupta S, Sussman I. Hyperglycemia, diabetes, and vascular disease. New York : Oxford University Press, 1992 : 3-20.
3. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 2003 ; 18 : 113-9. (Pubitemid 36104486)
4. Muntoni S, Atzori L, Mereu R, Manca A, Satta G, Gentilini A. Risk factors for cardiovascular disease in Sardinia from 1978 to 2001: a comparative study with Italian mainland. Eur J Intern Med 2009 ; 20 : 373-7.
5. Reddy K. Cardiovascular disease in India. World Health Stat 1993 ; 46 : 101-7.
6. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991 ; 286 : 152-4.
7. Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 1998 ; 62 : 20-4. (Pubitemid 28093829)
8. van Himbergen TM, van Tits LJH, Roest M, Stalenhoef AFH. The story of PON1: how an organophosphate hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 2006 ; 64 : 34-8. (Pubitemid 43285584)
9. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein associated serum paraoxonase-1 (PON1) is essential for PON1 mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006 ; 281 : 7657-65. (Pubitemid 43847536)
10. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009 ; 410 : 1-12.
11. Marta T, Glòria L, Mariano S, Jaume M. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 2004 ; 57 : 557-69.
12. Hanaa L, Noreddine G, Hassan T, Anass K, Loubna ER, Benyounes R, et al. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol 2008 ; 2 : 43-50.
13. Cherki M, Derouiche A, Drissi A, El Messal M, Bamou Y, Idrissi-Ouadghiri A, et al. Consumption of argan oil may have an antiatherogenic effect by improving paraoxonase activities and antioxidant status: intervention study in healthy men. Nutr Metab Cardiovasc Dis 2005 ; 15 : 352-60. (Pubitemid 41578780)
14. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972 ; 18 : 499-502.
15. Moti H, Michal B, Daniel B, Solomon B, Eran G, Henrietta R, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease. Circulation 1999 ; 100 : 475-82.
16. Forman D, Bulwer BE. Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle. Curr Treat Options Cardiovasc Med 2006 ; 8 : 47-57. (Pubitemid 43137245)
17. Mach F. Effets thérapeutiques et pléiotropiques des statines dans la prévention primaire et secondaire des maladies cardiovasculaires.Rev Med Suisse 2002 ; 60 : 967-70.
18. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001 ; 21 : 1451-7. (Pubitemid 34219807)
19. Arakawa K. Effect of exercise on hypertension and associated complications. Hypertens Res 1996 ; 19 : 87-91.
20. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999 ; 19 : 330-5. (Pubitemid 29072747)
21. Mackness MI, Harty D, Bhatnagar D,Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991 ; 86 : 193-9.
22. Flekac M, Skrha J, Zídková K, Lacinová Z, Hilgertová J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008 ; 57 : 717-26.
23. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-I. Clin Sci 2004 ; 107 : 435-47. (Pubitemid 39506735)
24. Mackness B, Durrington PN, Mackness MI. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004 ; 15 : 399-404.
25. Boemi M, Leview I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to nondiabetics, first degree relatives, influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001 ; 155 : 229-35. (Pubitemid 32167144)
26. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002 ; 32 : 256-9.
27. Lapalu J, Lahyani A, Borget I, Christin-Maitre S, Duron F, Fromigue J, et al. Évaluation de l'atteinte des objectifs du traitement hypolipémiant et de l'observance chez 100 patients atteints de diabète de type 2. J Pharm Clin 2007 ; 26 : 91-100. (Pubitemid 47035303)
28. Kalmar T, Seres I, Balogh Z, Kaplar M, Winkler G, Paragh G. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab 2005 ; 31 : 574-80. (Pubitemid 43001175)
29. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997 ; 46 : 1354-9. (Pubitemid 27315286)
30. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein deficient serum: relevance to diabetes. Atherosclerosis 2006 ; 187 : 74-81.
31. Poh R, Muniandy S. Paraoxonase 1 activity as a predictor of cardiovascular disease in type 2 diabetes. Southeast Asian J Trop Med Public Health 2010 ; 41 : 1231-46.
32. Maritim C, Sanders R, Watkins JB. Effects of ß-lipoic acid on biomarkers of oxidative stress in streptozotocin induced diabetic rats. J Nutr Biochem 2003 ; 14 : 288-94. (Pubitemid 36794267)
33. Karabina SA, Lehner AN, Frank E, Parthasarathy S, Santanam N. Oxidative inactivation of paraoxonase implications in diabetes mellitus and atherosclerosis. Biochim Biophys Acta 2005 ; 1725 : 213-21. (Pubitemid 41253931)
34. Clement EF, Rebecca JR, Sharon LS, Lucio GC, Arno GM. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/ arylesterase. Anal Biochem 1998 ; 180 : 242-7.
35. Gross ER, Ladisia JF, Weihrauch D, Olson LE, Kress TT, Hettrick DA, et al. Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. Am J Physiol Heart Circ Physiol 2003 ; 28 : 1552-9.
36. Kalousova M, Zima T, Tesar V, Dusilova SS, Skrha J. Advanced glycoxidation end products in chronic diseases -clinical chemistry and genetic background. Mutat Res 2005 ; 579 : 37-46. (Pubitemid 41540131)
37. Fortunato G, Rubba P, Panicco S, Trono D, Tinto N, Mazzakkara C. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 2003 ; 167 : 141-8. (Pubitemid 36255646)